INVESTOR RELATIONS

WALTHAM, Mass. and LONDON , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans on presenting at the Chardan Genetic Medicines Conference ,

WALTHAM, Mass. and LONDON , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the closing of its underwritten public offering of 4,600,000 American Depositary

WALTHAM, Mass. and LONDON , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans on presenting at the Cell & Gene Meeting on the Mesa

WALTHAM, Mass. and LONDON , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the pricing of an underwritten public offering of 4,000,000 American Depositary

WALTHAM, Mass. and LONDON , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that it has commenced an underwritten public offering of 4,000,000 American

NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses Preliminary efficacy signals observed in 3/3 patients in cohort 3 and 2/6 patients in cohorts 4 and 5, including

WALTHAM, Mass. and LONDON, United Kingdom , Sept. 13, 2018 (GLOBE NEWSWIRE) --   Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company has appointed strategic biotechnology

Regenerative Medicine Advanced Therapy (RMAT) Designation received in June 2018 for NSR-REP1 in Choroideremia Preliminary data from Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigmentosa expected at EURETINA 2018 in Vienna, Austria in September 2018 R&D Day planned for September 24, 2018 in New

WALTHAM, Mass. and LONDON , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ: NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans on presenting at the 2018 Wedbush PacGrow Healthcare

First gene therapy RMAT designation for an inherited retinal disease STAR Phase 3 registrational trial ongoing and FDA interactions planned RMAT designation enables closer and more frequent multidisciplinary interaction with FDA with all of the benefits of breakthrough therapy designation WALTHAM,

Preliminary data from dose escalation study in the Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigmentosa expected ahead of schedule in  Q3  2018 Dose expansion study in the XIRIUS trial expected to begin enrollment in Q4 2018 WALTHAM, Mass. and LONDON , June 06, 2018 (GLOBE NEWSWIRE) --

LEXINGTON, Mass. and LONDON , May 31, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans on presenting at the Jefferies 2018 Global Healthcare

LEXINGTON, Mass. and LONDON , April 30, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the Deutsche Bank 43 rd Annual Health Care

Presentations to Include Long-term Clinical Data on NSR-REP1 and Natural History Data in Choroideremia LEXINGTON, Mass. and LONDON , April 23, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal

- Recent initiation of STAR phase 3 trial in Choroideremia - - Begins 2018 with a cash position over $129 million - LEXINGTON, Mass. and LONDON , April 03, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare